PA SB190

Establishes a 7-member Pharmaceutical Transparency Review Board appointed by the Governor and legislative leaders to review high-cost prescription drugs and develop affordability recommendations for Pennsylvania residents, government agencies, health plans, and employers

Requires manufacturers to report detailed cost information for drugs costing at least $5,000 annually that have increased 50% or more over five years or 15% or more in 12 months, including R&D costs, clinical trial expenses, marketing spending, profits, and rebates

Creates the Pharmaceutical Transparency Review Fund in the State Treasury, funded by assessments on manufacturers based on their share of prescription drug sales revenue in Pennsylvania

Authorizes penalties of $20,000 per day per drug for manufacturers that fail to comply with reporting requirements

Mandates board reports by January 2028 on prescription drug affordability recommendations and by June 2026 on the generic drug market, with annual reports on price trends due each December 31